Korro Bio, Inc. KRRO 深 沪
已收盘 05-22 16:00:00 美东时间
11.61
+0.410
+3.66%
华盛通- 最 高12.17
- 今 开11.32
- 成交量 23.12万股
- 最 低 11.25
- 昨 收 11.20
- 总市值 1.67亿
- 52周最高 55.89
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 5.2044
- 委 比 75.39%
- 总股本 1442.26万
- 历史最高 2918.50
- 量 比 1.37
- 振 幅 8.21%
- 历史最低 5.2044
- 每 手 1
- 风险率 11.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21
Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rating and announces Price Target of $21.
05-18 21:34
Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49) per share from the
05-07 20:30
Korro Bio Presents Oral, Poster Presentations Of Data From Its Oligonucleotide Delivery Based RNA Editing Technology
Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster
04-16 19:34
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Raymond James Upgrades Korro Bio to Outperform, Announces $23 Price Target
Raymond James analyst Steven Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Outperform and announces $23 price target.
03-13 19:51
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the
03-13 04:20
Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
03-09 19:36
